% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Chatzikonstantinou:241121,
      author       = {G. Chatzikonstantinou and M. Diefenhardt and M. Fleischmann
                      and M. Meissner and C. Scherf and M. Trommel and U. Ramm and
                      C. Rödel$^*$ and N. Tselis and J. Licher},
      title        = {{C}ustomized 3{D}-printed molds for high
                      dose-ratebrachytherapy in facial skin cancer: {F}irst
                      clinical experience.[3{D}-gedruckte {M}oulagen für die
                      individualisierte {HDR}-{B}rachytherapie kutaner {M}alignome
                      im {G}esichtsbereich: {E}rste klinische {E}rfahrungen.]},
      journal      = {Journal der Deutschen Dermatologischen Gesellschaft},
      volume       = {21},
      number       = {1},
      issn         = {1610-0379},
      address      = {Berlin},
      publisher    = {Wiley-Blackwell},
      reportid     = {DKFZ-2023-00241},
      pages        = {35 - 43},
      year         = {2023},
      note         = {english version: Doi:10.1111/ddg.14944},
      abstract     = {Background and Objective: Radiotherapy of elderly, frail
                      patients with facial skin cancer in proximity to critical
                      organs is challenging. This is the first report on clinical
                      experience with facial skin cancer treated by individualized
                      3D-printer-basedmold high-dose-rate (HDR) brachytherapy
                      (BT). Patients and Methods: Fifteen patients not eligible
                      for radical surgery or definitive external beam radiotherapy
                      (EBRT) were treated with 3D-printer-based moldHDR-BT.
                      Patient selection and treatment were in accordance with
                      multidisciplinary tumor board recommendations.
                      Clinicalresponse, toxicity and cosmesis were analyzed.
                      Results: Median age was 77 years. Histology revealed
                      squamous cell carcinomain seven, basal cell carcinoma in
                      five, melanoma in situ in one, Lentigo maligna in one, and
                      melanoma in one patient, respectively. Median prescription
                      dosewas 39 Gy delivered in once-daily fractions of 3 Gy.
                      After a median follow-up of 12.2 months, local recurrence
                      was observed in one patient with melanoma in situ. Apart
                      from one grade 4 cataract, no other >grade 2 late toxicity
                      was documented. Conclusions: HDR-BT with 3D-printer-based
                      molds for facial skin cancer is a well-tolerated and safe
                      treatment option for elderly, frail patients not eligible
                      for radicalsurgery or definitive EBRT due to functional
                      inoperability or tumor location.},
      cin          = {FM01},
      ddc          = {610},
      cid          = {I:(DE-He78)FM01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:36721945},
      doi          = {10.1111/ddg.14944_g},
      url          = {https://inrepo02.dkfz.de/record/241121},
}